The Medicines Company (MDCO) PT Trimmed to $50 at Leerink After Removing MDCO-216
- Wall St. set to rise ahead of Trump inauguration
- General Electric (GE) Reports In-Line Q4 EPS
- Procter & Gamble (PG) Tops Q2 EPS by 2c
- Bristol-Myers Squibb (BMY) Says It Won't Pursue Accelerated U.S. Regulatory Pathway for Opdivo Plus Yervoy in Lung Cancer
- Dollar recoups losses, caution sets in ahead of Trump inauguration
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
Leerink Partners analyst Joseph Schwartz reiterated an Outperform rating but trimmed his price target on The Medicines Company (NASDAQ: MDCO) to $50.00 (from $53.00) after removing MDCO-216 from their model after the company announced the immediate discontinuation of its MDCO-216 (APoA-1 Milano) clinical development program for this investigational cholesterol efflux promoter.
Schwartz commented, "The MILANO-PILOT trial reportedly did not show efficacy on intracoronary atherosclerotic plaque, although the drug did maintain its strong safety profile. Many investors had low confidence in this program's probability of success and worried about future development costs, so there is some silver lining to this negative news in regard to near-term development cost savings that can be reallocated to other pipeline programs. Reiterate Outperform, and we are reducing our price target to $50 (from $53) by removing MDCO-216 from our model."
Shares of The Medicines Company closed at $32.52 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Synergy Pharmaceuticals (SGYP) PT Raised to $18 at Rodman & Renshaw Following FDA Approval
- Polaris Industries (PII) PT Raised to $75 at Wedbush
- Polaris Industries (PII) PT Raised to $75 at Wedbush; Reiterates Neutral
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst PT Change, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!